BioEclipse Therapeutics is working to develop a new generation of precise, targeted, immunotherapies that bring hope to patients with advanced cancer who have few treatment options.
The first therapeutic from our platform, now entering Phase 1, was developed for increased potency that provides three non-overlapping mechanisms of action to conquer the challenges of resistant and recurrent cancers and for the ability to scale in our low-cost manufacturing process.